(1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.

Frank Bloos Jürgen Held Stefan Kluge Philipp Simon Klaus Kogelmann Geraldine de Heer Sven-Olaf Kuhn Dominik JarczakJohann MotschGunther HempelNorbert WeilerAndreas Weyland Matthias Drüner Matthias Gründling Patrick Meybohm Daniel Christoph Richter Ulrich Jaschinski Onnen MoererUlf GüntherDirk SchädlerRaphael WeissChristian PutensenIxchel Castellanos Oliver Kurzai Peter Schlattmann Oliver Andreas Cornely Michael Bauer Daniel O Thomas-Rüddelnull null

Published in: Intensive care medicine (2022)

Serum BDG guided antifungal treatment did not improve 28-day mortality among sepsis patients with risk factors for but unexpected low rate of IC. This study cannot comment on the potential benefit of BDG-guidance in a more selected at-risk population.

Keyphrases

candida albicans
acute kidney injury
septic shock
intensive care unit
cardiovascular events
stem cells
cardiovascular disease
risk factors
clinical trial
combination therapy
risk assessment
human health
replacement therapy